43 Parkway Life REIT IHH holds a 32.95% equity stake in Parkway Life Real Estate Investment Trust (PLife REIT), one of Asia’ largest listed healthcare REITs by asset size. PLife REIT invests in income-producing real estate and related assets used mainly for healthcare and healthcare-related purposes. The trust owns a diversified portfolio of 75 properties worth about S$2.46 billion (approximately RM8.44 billion) as at 31 December 2024. Key Growth Areas • Drove gains from portfolio diversification • Disciplined capital management Performance Indicators Financial Indicators FY2023 FY2024 Total revenue1 RM0.4 billion RM0.4 billion EBITDA RM0.3 billion RM0.3 billion Gearing2 35.6% 34.8% Performance Highlights • Strategically forayed into the European region with an acquisition of 11 nursing homes in France at about 3.6% below valuation. • Successful maiden equity funding raising (EFR) via private placement of approximately S$180 million (about RM596 million) to fully finance the France acquisition. • Strong risk management strategies, particularly with effective hedging. Outlook PLife REIT’s consistently strong performance is attributed to targeted acquisitions, strategic partnerships and effective capital management. Moving forward, it will continue to strengthen its core presence in Singapore while consolidating its position in Japan and Europe for sustainable growth and long-term value creation. 1 Includes inter-segment revenue. 2 From PLife REIT standalone perspective Laboratories IHH Laboratories aspires to be among the largest, most trusted and data-driven laboratory services groups in the world. It comprises Parkway Laboratories (Singapore), Premier Integrated Laboratories (Malaysia), Acibadem Labmed (Türkiye) and Agilus Diagnostics (India). Key Growth Areas • Improved EBITDA amid steady business growth • Expand offerings including high-end tests such as genomics Performance Highlights • Malaysia: Premier Integrated Labs (PIL) has made available over 3,500 specialty laboratory tests performed by Mayo Clinic Laboratories, including tests unavailable locally to facilitate diagnosis and care. • Singapore: Strategic expansion of the Anatomic Pathology Lab at our headquarters has yielded increased capacity, improved staff workspace, and the ability to implement initiatives focused on specialised testing, Performance Indicators Financial Indicators FY2023 FY2024 Total Revenue3 RM1.7 billion RM1.8 billion EBITDA RM0.3 billion RM0.4 billion Test volumes (million) 96 104 operational efficiency, and expedited turnaround times. • India: Agilus Diagnostics has launched advanced genome testing for faster cancer detection, reducing turnaround from three weeks to just three days. This enables personalised treatment recommendations, and empowers clinicians to make timely, informed decisions. • Türkiye: Acibadem LabMed successfully attained the updated ISO15189 certification, the international standard that recognises the quality and competence of medical laboratories. Outlook IHH Laboratories is shaping up as a distinct core business and strong growth engine for the Group. Our growing capabilities in high-end tests put us in an idea position to organically increase our market share. We are also fast becoming the partner of choice to healthcare service providers and consumers with growing interest in preventive health and diagnostics, precision medicine and general wellness. We will continue to leverage digitalisation of our core platforms to improve productivity and service delivery, driving operating costs down in the long run. Tapping on our strong partnerships and network, our laboratories are poised to grow their reach and serve populations with an increasing need of diagnostics to manage more complex diseases. 3 Includes inter-segment revenue
RkJQdWJsaXNoZXIy NDgzMzc=